German drugmaker earns FDA warning; Pfizer facility wins environmental recognition;

> Another non-U.S. drug manufacturer--Jenahexal Pharm in Germany--has been stung with an FDA warning as the regulator continues its ex-U.S. inspection blitz. Warning Letter

> Pfizer's ($PFE) Montreal manufacturing plant has won an innovation award for an environmentally friendly cleaning process. Pfizer release

> Pfizer's ($PFE) Loughbeg, Ireland, plant conforms to the ISO 50001 standard for improving building energy performance, which emphasizes improvements in energy efficiency, use and consumption. More

> U.K.-based Shire ($SHPGY) has filed for regulatory approval to produce its Gaucher disease drug, VPRIV, at its facility in Lexington, MA, freeing capacity at its Cambridge, MA, plant for Fabry disease treatment Replagal--both competitors of drugs from nearby Genzyme. Story

> Three Aurobindo Pharma workers sustained burns in a reactor explosion at an API plant in India.  News

> While "optimizing" its contracts with wholesalers, Novartis ($NVS) has halted deliveries to some in a pricing dispute. Report | Item

> Former KV Pharmaceutical ($KV.A) VP Melissa Hughes is suing the drugmaker, saying the company interfered with her stock options. Report

> Label maker ATL has signed a deal with Document Security Systems for use of the latter's AuthentiGuard technology in anti-counterfeiting labels. Story

> The Hong Kong Department of Health has directed APT Pharma to recall a batch of diabetes treatment Glupozide after a plastic fragment was found embedded in a tablet. Announcement

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.